latest news releases from the newsroom
Nymox Pharmaceutical Corporation
Nymox Reports Positive New Clinical Trial Data On Improvement in Urinary Urgency and Frequency Symptoms in Patients On NX-1207 Drug for Prostate Enlargement
HASBROUCK HEIGHTS, N.J., Dec. 3, 2008 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new data from a recently completed clinical trial of NX-1207, the Company's investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptoms of urgent need to urinate, and of frequency of urination. Compared to baseline, symptoms of urgency to urinate were reduced by 47% at 90 days after a single treatment with NX-1207 (p less than .001), and this improvement was maintained in the majority of patients without further treatment at 12 months (41% improvement, p less than .001). Compared to baseline, symptoms of frequency of urination were reduced by 43% at 90 days (p less than .001), and this improvement was also maintained without further treatment at one year in the majority of patients (35% improvement, p less than .001).
EnterConnect Announces New On-Demand Solution Package to Cut IT Costs in These Tough Recessionary Times
SAN JOSE, Calif., Dec. 3, 2008 (GLOBE NEWSWIRE) -- EnterConnect Inc. (OTCBB:ECNI), today announced it is offering special introductory pricing on the EnterConnect 9 Complete Platform package which provides on-demand portal solutions for businesses. With this latest offering, customers receive special pricing through December 31, 2008 on EnterConnect's full business portal product suite and free bundled integration services to implement their web-based IT projects quickly and cost-effectively. Customers can reduce IT costs quickly by consolidating their separate Intranet, Extranet and .com Web sites on EnterConnect's on-demand portal platform.